Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT05895201 is registered in ClinicalTrials.gov with Indiana University as lead sponsor.

NCT NCT05895201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05895201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Indiana University
Phase
Phase 1/2
Overall status
Withdrawn
Start date
November 30, 2023
Completion date
December 31, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, adult, acute myeloid leukemia, bone marrow transplant complications, chronic myelomonocytic leukemia, myelodysplastic syndromes